Search for: "Spectrum Pharmaceuticals"
Spectrum Pharmaceuticals Appoints George Tidmarsh, M.D., Ph.D, as Senior Vice President, Chief Scientific Officer
HSMN NewsFeed,
19 Jul 2010:
Biopharmaceuticals, Personnel[Spectrum Pharmaceuticals]
Spectrum Pharmaceuticals Appoints James E. Shields as Chief Commercial Officer
HSMN NewsFeed,
23 Jun 2010:
Biopharmaceuticals, Personnel[Spectrum Pharmaceuticals]
TopoTarget Announces New CEO to Prepare Commercialisation of Belinostat
HSMN NewsFeed,
23 Feb 2010:
Biopharmaceuticals, Personnel[TopoTarget]
Spectrum Pharmaceuticals Announces Results of FDA Meeting Regarding FUSILEV(R) sNDA under Review for Advanced Metastatic Colorectal Cancer
HSMN NewsFeed,
25 Jan 2010:
Biopharmaceuticals, Oncology, FDA[Spectrum Pharmaceuticals, FUSILEV, levoleucovorin, colorectal cancer]
ZEVALIN(R) Receives Positive Reimbursement Ruling Using Average Sales Price (ASP) Methodology
HSMN NewsFeed,
3 Nov 2009:
Biopharmaceuticals, Oncology, Reimbursement[Spectrum Pharmaceuticals, ZEVALIN, ibritumomab tiuxetan, non-Hodgkin’s Lymphoma]
FDA Designates Fast Track Status for Apaziquone (EOquin(R)) for Bladder Cancer
HSMN NewsFeed,
21 Jul 2009:
Biopharmaceuticals, FDA[Spectrum Pharmaceuticals, Allergan, Fast Track Designation, apaziquone, EOquin]
Spectrum Pharmaceuticals Acquires 100% of ZEVALIN, an FDA-Approved, Proprietary, Biological Drug for Non-Hodgkin's Lymphoma
HSMN NewsFeed,
16 Mar 2009:
Biopharmaceuticals, Oncology, Acquisitions[Spectrum Pharmaceuticals, RIT Oncology, ZEVALIN, Non-Hodgkin's Lymphoma]
Spectrum Pharmaceuticals Poised to Acquire 100% Interest in RIT Oncology LLC Joint Venture upon CTI's Fulfillment of Closing Conditions
HSMN NewsFeed,
23 Feb 2009:
Biopharmaceuticals, Oncology, Acquisitions[Spectrum Pharmaceuticals, Cell Therapeutics, RIT Oncology, ZEVALIN]
Treatment with the Zevalin(R) Therapeutic Regimen as Sole Therapy Produces 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma
HSMN NewsFeed,
22 Jan 2009:
Biopharmaceuticals, Oncology[Cell Therapeutics, Zevalin, ibritumomab tiuxetan, ocular adnexal lymphoma]
Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US
HSMN NewsFeed,
16 Dec 2008:
Biopharmaceuticals, Oncology[Cell Therapeutics, Spectrum Pharmaceuticals, RIT Oncology, Zevalin]
Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma
HSMN NewsFeed,
9 Dec 2008:
Biopharmaceuticals, Oncology[Cell Therapeutics, Zevalin]
FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review
HSMN NewsFeed,
1 Dec 2008:
Biopharmaceuticals, Oncology[Cell Therapeutics, Spectrum Pharmaceuticals, Zevalin]
Spectrum Pharmaceuticals Files Supplemental New Drug Application with FDA for FUSILEV(TM) in Colorectal Cancer
HSMN NewsFeed,
31 Oct 2008:
Biopharmaceuticals, Oncology[Spectrum Pharmaceuticals, FUSILEV, levoleucovorin, mCRC]
Spectrum Pharmaceuticals Launches FUSILEV(TM)
HSMN NewsFeed,
15 Aug 2008:
Biopharmaceuticals, Oncology[Spectrum Pharmaceuticals, FUSILEV, levoleucovorin]
Spectrum Pharmaceuticals Announces FUSILEV(TM) as Tradename for Levoleucovorin for Injection
HSMN NewsFeed,
17 Jun 2008:
Biopharmaceuticals[Spectrum Pharmaceuticals, FUSILEV, levoleucovorin]
New Drug Application Filing for Levoleucovorin Tablets Completed by Spectrum Pharmaceuticals, Inc.
HSMN NewsFeed,
5 Jun 2008:
Biopharmaceuticals, Oncology, FDA[Spectrum Pharmaceuticals, Levoleucovorin, osteosarcoma]
Data from Satraplatin SPARC Phase 3 Trial in Patients with Hormone-Refractory Prostate Cancer Progressing after Initial Chemotherapy Presented at 44th ASCO Annual Meeting
HSMN NewsFeed,
2 Jun 2008:
Biopharmaceuticals, Oncology[GPC Biotech, satraplatin, SPARC trial, prostate cancer]
Spectrum Pharmaceuticals Announces Sale of Injectable Generic Drugs to Sagent Pharmaceuticals, Inc.
HSMN NewsFeed,
9 May 2008:
Biopharmaceuticals, Generics[Spectrum Pharmaceuticals, Sagent Pharmaceuticals]
Par Pharmaceutical Acquires Spectrum Pharmaceutical's Interest In Sumatriptan Injection
HSMN NewsFeed,
7 May 2008:
Biopharmaceuticals[Par Pharmaceutical, Spectrum Pharmaceuticals, sumatriptan]
Spectrum Pharmaceuticals Receives $20 Million Cash Payment from Par Pharmaceutical for Sumatriptan Injection
HSMN NewsFeed,
7 May 2008:
Biopharmaceuticals[Spectrum Pharmaceuticals, Par Pharmaceutical, sumatriptan]
FDA Approves New Drug Application (NDA) for LEVOleucovorin, Spectrum's First Proprietary Oncology Drug
HSMN NewsFeed,
7 Mar 2008:
Biopharmaceuticals, Oncology, FDA[Spectrum Pharmaceuticals, Levoleucovorin, methotrexate, leucovorin, osteosarcoma]
Spectrum Pharmaceuticals Receives Approval from Canadian Authorities to Expand EOquin(R) Registrational, Phase 3 Clinical Trials into Canada
HSMN NewsFeed,
19 Feb 2008:
Biopharmaceuticals, Oncology, Regulatory[Spectrum Pharmaceuticals, EOquin, bladder cancer]
Spectrum Pharmaceuticals Strengthens Management; Appoints Oncologist Richard A. Bender, MD as Senior Vice President and Chief Medical Officer
HSMN NewsFeed,
11 Feb 2008:
Biopharmaceuticals, Personnel[Spectrum Pharmaceuticals]
Spectrum Pharmaceuticals Announces Arbitration Panel Ruling
HSMN NewsFeed,
6 Nov 2007:
Biopharmaceuticals, Licensing, Litigation[Spectrum Pharmaceuticals, GPC Biotech]
GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial
HSMN NewsFeed,
30 Oct 2007:
Biopharmaceuticals, Oncology[Spectrum Pharmaceuticals, GPC Biotech, SPARC trial, prostate cancer, Pharmion]
Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
HSMN NewsFeed,
7 Sep 2007:
Biopharmaceuticals, Oncology[Spectrum Pharmaceuticals, EOquin, bladder cancer]
Spectrum Pharmaceuticals Investigational New Drug Application for SPI-1620 Cleared by U.S. Food & Drug Administration
HSMN NewsFeed,
9 Aug 2007:
Biopharmaceuticals, Oncology, FDA[Spectrum Pharmaceuticals, SPI-1620]
GPC Biotech Withdraws Satraplatin NDA Filed for Accelerated Approval
HSMN NewsFeed,
30 Jul 2007:
Biopharmaceuticals, Oncology, FDA[GPC Biotech, satraplatin, prostate cancer]
Marketing Authorization Application for Satraplatin Accepted for Review by the European Medicines Agency
HSMN NewsFeed,
27 Jul 2007:
Biopharmaceuticals, Oncology, Regulatory[Spectrum Pharmaceuticals, Pharmion, satraplatin, prostate cancer]
Spectrum Pharmaceuticals Acquires From Indena Worldwide Rights To Ortataxel, A Phase 2 Third Generation Taxane
HSMN NewsFeed,
25 Jul 2007:
Biopharmaceuticals, Oncology, Licensing[Spectrum Pharmaceuticals, Indena S.p.A., ortataxel, taxane]
FDA Oncologic Drugs Advisory Committee Recommends that FDA Wait for Overall Survival Results from Satraplatin Phase 3 Trial
HSMN NewsFeed,
24 Jul 2007:
Biopharmaceuticals, Oncology, FDA[GPC Biotech, SPARC trial, satraplatin, prostate cancer]
Spectrum Strengthens Management With the Appointment of George Uy, an Industry Veteran, as Vice President, Marketing Oncology/Urology
HSMN NewsFeed,
11 Jul 2007:
Biopharmaceuticals, Oncology, Urology, Personnel[Spectrum Pharmaceuticals, George Uy]
GPC Biotech Announces that Partner Pharmion Submits European Marketing Application for Satraplatin
HSMN NewsFeed,
26 Jun 2007:
Biopharmaceuticals, Oncology[GPC Biotech, Pharmion, satraplatin, prostate cancer, HRPC]
GPC Biotech Announces Partnering Agreement for Satraplatin for Japan with Yakult
HSMN NewsFeed,
25 Jun 2007:
Biopharmaceuticals, Oncology, Licensing[GPC Biotech, Yakult, satraplatin]
Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
HSMN NewsFeed,
4 Jun 2007:
Biopharmaceuticals, Oncology[Pharmion, GPC Biotech, satraplatin, prostate cancer]
Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at Annual Meeting of American Urological Association
HSMN NewsFeed,
23 May 2007:
Biopharmaceuticals, Urology[Spectrum Pharmaceuticals, ozarelix, benign prostatic hypertrophy]
Additional Satraplatin Efficacy Data From Phase 3 SPARC Trial Presented at Annual Meeting of American Urological Association
HSMN NewsFeed,
21 May 2007:
Biopharmaceuticals, Oncology, Urology[Spectrum Pharmaceuticals, satraplatin, SPARC trial, prostate cancer]
Spectrum Pharmaceuticals Announces FDA'S Oncology Drug Advisory Committee to Review Satraplatin for the Treatment of Hormone Refractory Prostate Cancer
HSMN NewsFeed,
15 May 2007:
Biopharmaceuticals, Oncology[Spectrum Pharmaceuticals, satraplatin, prostate cancer]
Spectrum Pharmaceuticals Initiates Phase 3, Registrational Trials With EOquin(R) in Non-Invasive Bladder Cancer
HSMN NewsFeed,
2 May 2007:
Biopharmaceuticals, Drug Delivery, Urology, Oncology[Spectrum Pharmaceuticals, EOquin, apaziquone, bladder cancer]
FDA Accepts Satraplatin NDA And Grants Priority Review
HSMN NewsFeed,
16 Apr 2007:
Biopharmaceuticals, Oncology, FDA[Spectrum Pharmaceuticals, satraplatin, prostate cancer]
FDA Accepts GPC Biotech's Satraplatin NDA for Filing and Grants Priority Review Status
HSMN NewsFeed,
16 Apr 2007:
Biopharmaceuticals, Oncology[GPC Biotech, Pharmion, satraplatin, prostate cancer]
Satraplatin Phase 3 SPARC Trial - Additional Data Presented at European Association of Urology Congress
HSMN NewsFeed,
22 Mar 2007:
Biopharmaceuticals, Oncology[Spectrum Pharmaceuticals, satraplatin, SPARC trial, prostate cancer]
Additional Data from Satraplatin SPARC Phase 3 Trial Presented at European Association of Urology Congress
HSMN NewsFeed,
22 Mar 2007:
Biopharmaceuticals, Oncology[GPC Biotech, Pharmion, satraplatin, SPARC trial, prostate cancer]
Spectrum Pharmaceuticals Bolsters Ozarelix Team with Addition of In-House Urology Expert Bela S. Denes, MD, FACS
HSMN NewsFeed,
19 Mar 2007:
Biopharmaceuticals, Urology, Personnel[Spectrum Pharmaceuticals]
Satraplatin Shown to Significantly Reduce Risk of Disease Progression in Advanced Hormone-Refractory Prostate Cancer Patients
HSMN NewsFeed,
23 Feb 2007:
Biopharmaceuticals, Oncology[Pharmion, GPC Biotech, SPARC trial, satraplatin, prostate cancer]
Spectrum Pharmaceuticals Announces Satraplatin Data Presentation at the American Society of Clinical Oncology Prostate Cancer Symposium
HSMN NewsFeed,
23 Feb 2007:
Biopharmaceuticals, Oncology[Spectrum Pharmaceuticals, SPARC trial, satraplatin, prostate cancer]
GPC Biotech Launches Expanded Access Program for Oncology Drug Candidate Satraplatin in the U.S.
HSMN NewsFeed,
21 Feb 2007:
Biopharmaceuticals, Oncology[GPC Biotech, Satraplatin, SPERA program, prostate cancer]
GPC Biotech Submits NDA for Lead Oncology Drug Candidate Satraplatin
HSMN NewsFeed,
16 Feb 2007:
Biopharmaceuticals, Oncology, FDA[GPC Biotech, satraplatin, hormone refractory prostate cancer]
Spectrum Pharmaceuticals Announces Completion of NDA Filing for Satraplatin for Hormone Refractory Prostate Cancer
HSMN NewsFeed,
16 Feb 2007:
Biopharmaceuticals, Oncology, FDA[Spectrum Pharmaceuticals, satraplatin, hormone refractory prostate cancer]
Spectrum Pharmaceuticals Initiates Phase 2b Trial for Ozarelix in Patients with Benign Prostate Hypertrophy
HSMN NewsFeed,
25 Jan 2007:
Biopharmaceuticals, Urology[Spectrum Pharmaceuticals, ozarelix, benign prostate hypertrophy]
Spectrum Pharmaceuticals Announces FDA's Acceptance of Ozarelix IND and Approval of Phase 2b Protocol in BPH (Benign Prostate Hypertrophy)
HSMN NewsFeed,
3 Jan 2007:
Biopharmaceuticals, Urology[Spectrum Pharmaceuticals, ozarelix, Benign Prostate Hypertrophy]
Spectrum Pharmaceuticals Announces That Sumatriptan Injection Litigation With GlaxoSmithKline(R) Has Been Dismissed Pursuant to the Settlement Agreement
HSMN NewsFeed,
21 Dec 2006:
Biopharmaceuticals, Generics, Litigation[Spectrum Pharmaceuticals, sumatriptan, Imitrex, GlaxoSmithKline]
Spectrum Pharmaceuticals Files Arbitration Claim Against GPC Biotech AG for Violations of Satraplatin License Agreement
HSMN NewsFeed,
14 Dec 2006:
Biopharmaceuticals, Licensing, Litigation[Spectrum Pharmaceuticals, GPC Biotech]
GPC Biotech Responds to Arbitration Claim by Spectrum Pharmaceuticals
HSMN NewsFeed,
13 Dec 2006:
Biopharmaceuticals, Licensing, Litigation[GPC Biotech, Spectrum Pharmaceuticals, satraplatin]
Par Pharmaceutical Announces Agreement With GlaxoSmithKline to Settle Imitrex(R) Injection Patent Litigation
HSMN NewsFeed,
13 Nov 2006:
Biopharmaceuticals, Generics, Litigation[Par Pharmaceutical, Spectrum Pharmaceuticals, GlaxoSmithKline, Imitrex]
Spectrum Pharmaceuticals Announces Agreement With GlaxoSmithKline to Settle Imitrex(R) Injection Patent Litigation
HSMN NewsFeed,
13 Nov 2006:
Biopharmaceuticals, Generics, Litigation[Spectrum Pharmaceuticals, GlaxoSmithKline, sumatriptan, Imitrex]
Spectrum Pharmaceuticals Announces Positive Phase 2 Data with Ozarelix in Patients with Benign Prostatic Hypertrophy
HSMN NewsFeed,
3 Oct 2006:
Biopharmaceuticals, Urology[Spectrum Pharmaceuticals, Benign Prostatic Hypertrophy, ozarelix]
AEterna Zentaris Announces Positive Phase 2 Results for Ozarelix in Benign Prostatic Hyperplasia
HSMN NewsFeed,
3 Oct 2006:
Biopharmaceuticals, Urology[AETERNA ZENTARIS, ozarelix, benign prostatic hypertrophy]
Spectrum Pharmaceuticals Announces Positive Results of Satraplatin Pivotal Phase 3 Trial in Patients with Hormone-Refractory Prostate Cancer
HSMN NewsFeed,
24 Sep 2006:
Biopharmaceuticals, Oncology[Spectrum Pharmaceuticals, GPC Biotech, satraplatin, prostate cancer]
Pharmion Corporation and GPC Biotech Announce Positive Results from the Satraplatin Pivotal Phase 3 Trial and Achievement of the Progression-Free Survival Endpoint
HSMN NewsFeed,
24 Sep 2006:
Biopharmaceuticals, Oncology[Pharmion, GPC Biotech, Spectrum Pharmaceuticals, satraplatin, prostate cancer]
Spectrum Pharmaceuticals Announces Phase 2 Data for Ozarelix in Hormone-Dependent Prostate Cancer
HSMN NewsFeed,
2 Aug 2006:
Biopharmaceuticals, Oncology[Spectrum Pharmaceuticals, ozarelix, LHRH antagonist, prostate cancer]
Spectrum Pharmaceuticals Announces Initiation of Phase 2 Trial Evaluating Satraplatin in Combination With Tarceva in Patients With Inoperable, Advanced Non-small Cell Lung Cancer
HSMN NewsFeed,
2 Aug 2006:
Biopharmaceuticals, Oncology[Spectrum Pharmaceuticals, GPC Biotech, satraplatin, Tarceva, erlotinib]
AEterna Zentaris Announces Positive Phase 2 Results for Ozarelix (D-63153) in Hormone-Dependent Inoperable Prostate Cancer
HSMN NewsFeed,
2 Aug 2006:
Biopharmaceuticals, Oncology[AETERNA ZENTARIS, ozarelix, prostate cancer]
GPC Biotech Initiates Phase 2 Randomized Trial Evaluating Satraplatin plus Tarceva(R) in Patients with Advanced Non-Small Cell Lung Cancer
HSMN NewsFeed,
2 Aug 2006:
Biopharmaceuticals, Oncology[GPC Biotech, satraplatin, Tarceva, erlotinib, OSI Pharmaceuticals]
Independent Data Monitoring Board Recommends That Satraplatin Phase 3 Trial Continue as Planned
HSMN NewsFeed,
8 Jun 2006:
Biopharmaceuticals, Oncology[Spectrum Pharmaceuticals, satraplatin , prostate cancer, SPARC trial]
Independent Data Monitoring Board Recommends Expedited Interim Analysis of Overall Survival Data for Satraplatin Phase 3 Trial
HSMN NewsFeed,
17 May 2006:
Biopharmaceuticals[Spectrum Pharmaceuticals, GPC Biotech, satraplatin, SPARC trial]
Independent Data Monitoring Board Recommends That Satraplatin Phase 3 Trial Continue as Planned
HSMN NewsFeed,
25 Apr 2006:
Biopharmaceuticals, Oncology[Pharmion, satraplatin, SPARC trial]
Spectrum Pharmaceuticals Completes Acquisition of Oncology Drug Assets of Targent, Inc.
HSMN NewsFeed,
21 Apr 2006:
Biopharmaceuticals, Acquisitions[Spectrum Pharmaceuticals, Targent, Levofolinic acid]
Spectrum Pharmaceuticals Announces Presentation of EOquin(TM) Phase 2 Data at the 21st European Association of Urology Annual Congress in Paris, France
HSMN NewsFeed,
6 Apr 2006:
Biopharmaceuticals, Oncology, Urology[Spectrum Pharmaceuticals, EOquin, bladder cancer]
Spectrum Pharmaceuticals to Acquire NDA for an Oncology Drug and other Assets
HSMN NewsFeed,
20 Mar 2006:
Biopharmaceuticals, Oncology, Mergers & Acquisitions[Spectrum Pharmaceuticals, Targent, levofolinic acid]
Spectrum Pharmaceuticals Advances EOquin(TM) Towards Registration & Expects to Initiate Phase 3 Study In 2006
HSMN NewsFeed,
14 Mar 2006:
Biopharmaceuticals, Oncology, FDA[Spectrum Pharmaceuticals, EOquin , bladder cancer]
Spectrum Strengthens Management Team by Appointing Industry Veteran as Vice President of Medical Affairs
HSMN NewsFeed,
2 Mar 2006:
Biopharmaceuticals, Personnel[Spectrum Pharmaceuticals]
Spectrum Pharmaceuticals announces Presentation of New Satraplatin Clinical Data from Pharmacokinetics Study at ASCO Prostate Cancer Symposium
HSMN NewsFeed,
27 Feb 2006:
Biopharmaceuticals, Oncology[Spectrum Pharmaceuticals, Satraplatin]
Par Pharmaceutical Announces Product Collaboration with Spectrum Pharmaceuticals, Inc.
HSMN NewsFeed,
23 Feb 2006:
Biopharmaceuticals[Par Pharmaceutical, Spectrum Pharmaceuticals]
American Pharmaceutical Partners and American BioScience Announce Senior Management Team of Abraxis BioScience
HSMN NewsFeed,
14 Feb 2006:
Biopharmaceuticals, Personnel, Mergers & Acquisitions[American Pharmaceutical Partners, American BioScience, Abraxis BioScience]
Spectrum Issues Update on Satraplatin
HSMN NewsFeed,
23 Jan 2006:
Biopharmaceuticals, Oncology[Spectrum Pharmaceuticals, GPC Biotech, Pharmion, satraplatin]
Additional items found: The Network Archive contains
76 additional itemsSpectrum Pharmaceuticals
Public
Feeds 
Full text >>
